LaSap vaccine: Immunotherapy and immunochemotherapy associated with allopurinol in dogs naturally infected with Leishmania infantum

Parasite Immunol. 2024 Feb;46(2):e13028. doi: 10.1111/pim.13028.

Abstract

Canine visceral leishmaniasis is a parasitic zoonosis that has a profound impact on public health in countries where it is endemic. Chemotherapeutic treatments cannot keep dogs stable for long periods, and the risk of generating parasitic resistance must be considered. Forty-four symptomatic and naturally infected dogs with Leishmania infantum were tested with two treatment protocols (i) immunotherapy with LaSap vaccine and (ii) immunochemotherapy with LaSap vaccine plus allopurinol. At 90 days after the end of the treatment, it was verified that, although both protocols had generated significant clinical improvements with a greater production of IFN-γ/IL-10, in relation to the parasite load, mainly in the skin, the dogs treated only with immunotherapy maintained the same profile. These results indicate that LaSap is a good strategy to control dog parasitism.

Keywords: canine visceral leishmaniasis; immunochemotherapy; immunotherapy.

MeSH terms

  • Allopurinol / therapeutic use
  • Animals
  • Dog Diseases* / drug therapy
  • Dog Diseases* / prevention & control
  • Dogs
  • Immunotherapy / methods
  • Leishmania infantum*
  • Leishmaniasis, Visceral* / drug therapy
  • Leishmaniasis, Visceral* / prevention & control
  • Leishmaniasis, Visceral* / veterinary
  • Vaccines*

Substances

  • Allopurinol
  • Vaccines